Skip to content

Study · Animal study (in vivo) · rat · 2016

6 results

Effect of teriparatide on repair of femoral metaphyseal defect in ovariectomized rats.

Tao ZS, Lv YX, Cui W, Huang ZL, Tu KK, Zhou Q, Sun T, Yang L

Zeitschrift fur Gerontologie und Geriatrie10 Sept 2015Cited by 22 (Europe PMC)

PMID26358080 (opens in a new tab)DOI10.1007/s00391-015-0949-1 (opens in a new tab)PepBankPUB-26358080
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized rats, teriparatide increased bone formation in femoral defects compared with control.

    In plain wordsIn rats, teriparatide increased bone formation in femoral defects compared with control.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone formation in defect area
    Study

    ratn: not reported in source

    Ovariectomized female Sprague-Dawley rats with femoral metaphyseal defects
    Comparator
    Control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 μg/kg three times per week · intraperitoneal · 4 and 8 weeksAs given in this study (rat).

    Source sentences

    Summary
    PTH increased bone formation in the defect area.
    3 context sentences
    Summary · context
    The PTH group and control group were compared 4  and 8 weeks after surgery.
    Summary · context
    Female Sprague-Dawley rats were ovariectomized and after 3 months a critically sized defect of 3 mm in diameter-a through-hole bone defect-was drilled into each distal femur of the ovariectomized rats.
    Summary · context
    The rats were injected with teriparatide (30 μg/kg) parathyroid hormone (PTH) in the peritoneum three times per week. After 4 and 8 weeks the animals were killed and the blood and bilateral femora were harvested for biochemical analysis, histopathological observation, and micro-computed tomography (CT) examination.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized rats, teriparatide showed the strongest effects on bone microarchitecture measures and fluorescence-marked new bone area, without stated directions.

    In plain wordsIn rats, teriparatide affected bone structure measures and marked new bone area, but the abstract did not state their directions.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Direction not reportedBone microarchitecture and new bone area
    Study

    ratn: not reported in source

    Ovariectomized female Sprague-Dawley rats with femoral metaphyseal defects
    Comparator
    Control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 μg/kg three times per week · intraperitoneal · 4 and 8 weeksAs given in this study (rat).

    Source sentences

    Summary
    Moreover, PTH showed the strongest effects on bone volume per total volume, trabecular number, trabecular thickness, trabecular separation, and total fluorescence-marked new bone area.
    2 context sentences
    Summary · context
    Female Sprague-Dawley rats were ovariectomized and after 3 months a critically sized defect of 3 mm in diameter-a through-hole bone defect-was drilled into each distal femur of the ovariectomized rats.
    Summary · context
    The rats were injected with teriparatide (30 μg/kg) parathyroid hormone (PTH) in the peritoneum three times per week. After 4 and 8 weeks the animals were killed and the blood and bilateral femora were harvested for biochemical analysis, histopathological observation, and micro-computed tomography (CT) examination.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized rats, teriparatide reduced serum C-terminal telopeptide of type I collagen compared with control.

    In plain wordsIn rats, teriparatide reduced serum C-terminal telopeptide of type I collagen compared with control.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseSerum C-terminal telopeptide of type I collagen
    Study

    ratn: not reported in source

    Ovariectomized female Sprague-Dawley rats with femoral metaphyseal defects
    Comparator
    Control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 μg/kg three times per week · intraperitoneal · 4 and 8 weeksAs given in this study (rat).

    Source sentences

    Summary
    Additionally, the PTH treatment group showed inhibited serum concentrations of C-terminal telopeptide of type I collagen and enhanced expression of calcium, phosphorus, and bone alkaline phosphatase.
    2 context sentences
    Summary · context
    Female Sprague-Dawley rats were ovariectomized and after 3 months a critically sized defect of 3 mm in diameter-a through-hole bone defect-was drilled into each distal femur of the ovariectomized rats.
    Summary · context
    The rats were injected with teriparatide (30 μg/kg) parathyroid hormone (PTH) in the peritoneum three times per week. After 4 and 8 weeks the animals were killed and the blood and bilateral femora were harvested for biochemical analysis, histopathological observation, and micro-computed tomography (CT) examination.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized rats, teriparatide enhanced calcium expression compared with control.

    In plain wordsIn rats, teriparatide enhanced calcium expression compared with control.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCalcium expression
    Study

    ratn: not reported in source

    Ovariectomized female Sprague-Dawley rats with femoral metaphyseal defects
    Comparator
    Control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 μg/kg three times per week · intraperitoneal · 4 and 8 weeksAs given in this study (rat).

    Source sentences

    Summary
    Additionally, the PTH treatment group showed inhibited serum concentrations of C-terminal telopeptide of type I collagen and enhanced expression of calcium, phosphorus, and bone alkaline phosphatase.
    2 context sentences
    Summary · context
    Female Sprague-Dawley rats were ovariectomized and after 3 months a critically sized defect of 3 mm in diameter-a through-hole bone defect-was drilled into each distal femur of the ovariectomized rats.
    Summary · context
    The rats were injected with teriparatide (30 μg/kg) parathyroid hormone (PTH) in the peritoneum three times per week. After 4 and 8 weeks the animals were killed and the blood and bilateral femora were harvested for biochemical analysis, histopathological observation, and micro-computed tomography (CT) examination.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized rats, teriparatide enhanced phosphorus expression compared with control.

    In plain wordsIn rats, teriparatide enhanced phosphorus expression compared with control.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePhosphorus expression
    Study

    ratn: not reported in source

    Ovariectomized female Sprague-Dawley rats with femoral metaphyseal defects
    Comparator
    Control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 μg/kg three times per week · intraperitoneal · 4 and 8 weeksAs given in this study (rat).

    Source sentences

    Summary
    Additionally, the PTH treatment group showed inhibited serum concentrations of C-terminal telopeptide of type I collagen and enhanced expression of calcium, phosphorus, and bone alkaline phosphatase.
    2 context sentences
    Summary · context
    Female Sprague-Dawley rats were ovariectomized and after 3 months a critically sized defect of 3 mm in diameter-a through-hole bone defect-was drilled into each distal femur of the ovariectomized rats.
    Summary · context
    The rats were injected with teriparatide (30 μg/kg) parathyroid hormone (PTH) in the peritoneum three times per week. After 4 and 8 weeks the animals were killed and the blood and bilateral femora were harvested for biochemical analysis, histopathological observation, and micro-computed tomography (CT) examination.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In ovariectomized rats, teriparatide enhanced bone alkaline phosphatase expression compared with control.

    In plain wordsIn rats, teriparatide enhanced bone alkaline phosphatase expression compared with control.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone alkaline phosphatase expression
    Study

    ratn: not reported in source

    Ovariectomized female Sprague-Dawley rats with femoral metaphyseal defects
    Comparator
    Control
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    30 μg/kg three times per week · intraperitoneal · 4 and 8 weeksAs given in this study (rat).

    Source sentences

    Summary
    Additionally, the PTH treatment group showed inhibited serum concentrations of C-terminal telopeptide of type I collagen and enhanced expression of calcium, phosphorus, and bone alkaline phosphatase.
    2 context sentences
    Summary · context
    Female Sprague-Dawley rats were ovariectomized and after 3 months a critically sized defect of 3 mm in diameter-a through-hole bone defect-was drilled into each distal femur of the ovariectomized rats.
    Summary · context
    The rats were injected with teriparatide (30 μg/kg) parathyroid hormone (PTH) in the peritoneum three times per week. After 4 and 8 weeks the animals were killed and the blood and bilateral femora were harvested for biochemical analysis, histopathological observation, and micro-computed tomography (CT) examination.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.